Investing in Project ECHO allowed Health Share to offer continuing education for providers, and many of them now say they enjoy participating in the program, said Christine Bernsten, senior manager of delivery systems transformation for Health Share of Oregon.
Investing in Project ECHO allowed Health Share to offer continuing education for providers, and many of them now say they enjoy participating in the program, said Christine Bernsten, senior manager of delivery systems transformation for Health Share of Oregon.
Transcript (slightly modified)
How did Health Share of Oregon get involved with Project ECHO?
So when CCOs were initially created, we received funding from the Oregon Health Authority to invest in transformative projects, and one of the projects that we initially invested in was called Project ECHO. Because we really saw this as a unique technology and model to link specialists with primary care and be able to provide education in a really accessible way around critical issues for our patient population.
Was there any provider trepidation with getting involved with Project ECHO?
So the providers that participate choose to participate, and they have an incentive of receiving the access to the specialists as well as an hour of free CME for every session that they participate in, so that’s been a nice and easy way to engage people. And I think once people do participate and get involved with this cohort of other providers, they really see the value of the education that they’re getting and they really enjoy participating once they get involved with it.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
2 Commerce Drive
Cranbury, NJ 08512